EPS for ResMed Inc. (RMD) Expected At $0.92

July 13, 2018 - By Darrin Black

ResMed Inc. (NYSE:RMD) LogoInvestors sentiment decreased to 1.2 in Q1 2018. Its down 0.31, from 1.51 in 2017Q4. It worsened, as 23 investors sold ResMed Inc. shares while 123 reduced holdings. 61 funds opened positions while 114 raised stakes. 87.19 million shares or 0.43% more from 86.81 million shares in 2017Q4 were reported.
Global X Ltd invested in 0.01% or 6,569 shares. Azimuth Ltd Liability Co holds 0.89% or 123,690 shares in its portfolio. Arizona State Retirement Sys, Arizona-based fund reported 110,900 shares. Cornercap Counsel Inc has 0.04% invested in ResMed Inc. (NYSE:RMD) for 2,736 shares. Legal & General Grp Pcl accumulated 737,142 shares. Bridgewater Assoc Limited Partnership holds 0.01% of its portfolio in ResMed Inc. (NYSE:RMD) for 9,632 shares. Lpl Fincl owns 0% invested in ResMed Inc. (NYSE:RMD) for 8,887 shares. Cubist Systematic Strategies Lc holds 0.05% or 8,371 shares in its portfolio. The North Carolina-based Atria Invests Llc has invested 0.03% in ResMed Inc. (NYSE:RMD). Moreover, Whittier Tru Communication has 0% invested in ResMed Inc. (NYSE:RMD) for 240 shares. Jane Street Lc holds 0% or 3,249 shares in its portfolio. Great West Life Assurance Communications Can invested 0.02% in ResMed Inc. (NYSE:RMD). Royal Bancorporation Of Canada, Ontario – Canada-based fund reported 40,213 shares. Pub Employees Retirement Systems Of Ohio holds 60,597 shares. Dekabank Deutsche Girozentrale holds 0.02% of its portfolio in ResMed Inc. (NYSE:RMD) for 25,372 shares.

Since January 24, 2018, it had 0 insider buys, and 23 selling transactions for $12.16 million activity. 25,934 shares were sold by WAREHAM JOHN P, worth $2.65 million. 2,810 ResMed Inc. (NYSE:RMD) shares with value of $291,538 were sold by PENDARVIS DAVID. SULPIZIO RICHARD sold $2.92M worth of stock or 28,403 shares. The insider Sandercock Brett sold $186,840. The insider McHale Richard sold $200,240. TAYLOR RONALD R sold $487,083 worth of stock.

Analysts expect ResMed Inc. (NYSE:RMD) to report $0.92 EPS on August, 7.They anticipate $0.15 EPS change or 19.48 % from last quarter’s $0.77 EPS. RMD’s profit would be $131.32 million giving it 29.63 P/E if the $0.92 EPS is correct. After having $0.92 EPS previously, ResMed Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.35% or $1.45 during the last trading session, reaching $109.02. About 680,503 shares traded or 3.76% up from the average. ResMed Inc. (NYSE:RMD) has risen 47.21% since July 13, 2017 and is uptrending. It has outperformed by 34.64% the S&P500.

ResMed Inc. (NYSE:RMD) Ratings Coverage

Among 4 analysts covering ResMed (NYSE:RMD), 0 have Buy rating, 1 Sell and 3 Hold. Therefore 0 are positive. ResMed had 4 analyst reports since January 23, 2018 according to SRatingsIntel. On Wednesday, April 4 the stock rating was downgraded by Citigroup to “Neutral”. The stock of ResMed Inc. (NYSE:RMD) earned “Hold” rating by Northland Capital on Tuesday, January 23. As per Tuesday, January 23, the company rating was downgraded by Macquarie Research. The firm has “Hold” rating by Needham given on Tuesday, January 23.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company has market cap of $15.56 billion. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud software informatics solutions to manage patient outcomes, as well as provides customer and business processes. It has a 54.87 P/E ratio. The firm also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators.

Another recent and important ResMed Inc. (NYSE:RMD) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares” on July 11, 2018.

ResMed Inc. (NYSE:RMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.